- Home
- Equipment
- australasia
- solid tumor
Refine by
Solid Tumor Equipment Supplied In Australasia
9 equipment items found
Manufactured by:Cartherics Pty ltd based inNotting Hill, AUSTRALIA
Indication: Solid tumors. Research: iT cells and macrophages [CARs+/- gene KOs]. ...
Manufactured by:Cartherics Pty ltd based inNotting Hill, AUSTRALIA
Indication: Solid tumors. Research: Descriptor iNK cells [other CAR targets / dual ...
Manufactured by:Cartherics Pty ltd based inNotting Hill, AUSTRALIA
Indication: Solid tumors. Research: CAR iNK cells + novel receptor fusion proteins. ...
Manufactured by:Biosceptre International Limited based inCambridge, UNITED KINGDOM
We are also developing antibodies that specifically target nfP2X7 for use in both solid and haematological tumours. Our preclinical data is very promising and studies show an excellent safety profile. By exploiting the modular nature of the antibody structure, the same panel of antibody sequences can be used to generate a variety of therapeutic antibody formats including, but not limited to, ...
by:Chimeric Therapeutics based inCarlton South, AUSTRALIA
CHM 1101 (CLTX CAR T) is an optimized first-in-class CAR T cell therapy that uniquely utilizes Chlorotoxin (CLTX), a 36-amino acid peptide derived from deathstalker scorpion venom as its tumour targeting ...
by:Chimeric Therapeutics based inCarlton South, AUSTRALIA
CHM 2101 (CDH17 CAR T) is an optimized 3rd generation CAR T cell therapy that is the first to target ...
by:AdAlta Limited based inBundoora, AUSTRALIA
AdAlta and Carina Biotech to develop next-generation i-body enabled CAR-T cancer therapeutics. AdAlta has entered a collaboration agreement with Carina Biotech to develop next-generation i-body enabled CAR-T cells, with the potential to bring CAR-T cell therapy to treat a far greater range of cancers than the small number of blood cancers that has been achieved today. Under the Collaboration ...
Manufactured by:INOVIQ Ltd based inNotting Hill, AUSTRALIA
In initial clinical studies, SubB2M has detected cancers with 100% sensitivity and specificity for mid to late-stage cancers, and >95% specificity and 100% sensitivity for early-stage cancers. There is also evidence that Neu5Gc is present in a wide range of solid human tumors and can be detected in serum using SubB2M. SubB2M has the potential to detect cancer ...
Manufactured by:Sartorius AG based inGoettingen, GERMANY
Innovation is at the heart of everything we do. Our proprietary drug delivery technology platform, Veltis®, uses engineered recombinant albumin to enhance albumin’s intrinsic characteristics for optimal therapeutic performance of your ...